NEW YORK, June 13, 2019 /PRNewswire/ -- Hoth Therapeutics,
Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique
targeted therapeutics for patients suffering from indications such
as atopic dermatitis–also known as eczema–as well
as dermatological and chronic wound disorders, today announced
that its Chief Executive Officer, Mr. Robb
Knie will be presenting on June 26,
2019 at the Union League of Philadelphia.
The Union League of Philadelphia is ranked the number one City
Club in the Country. In attendance will be the Broad Street
Angels ("BSA"), a Union League of Philadelphia affinity club comprised of
approximately 100 accredited investors. The BSA is a
member-led investors network focusing on early stage, high-growth
businesses in the Mid-Atlantic. For additional information please
visit; https://broadstreetangels.com/
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc.,
a Nevada corporation, is a biopharmaceutical company
focused on unique targeted therapeutics for patients suffering from
indications such as atopic dermatitis, also known as eczema. Hoth
has exclusive worldwide rights to the BioLexa Platform.
Forward Looking Statements
This press release includes
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release include, but are not limited to,
statements that relate to the advancement and development of the
BioLexa Platform, the commencement of clinical trials, the
availability of data from clinical trials and other information
that is not historical information. When used herein, words such as
"anticipate", "being", "will", "plan", "may", "continue", and
similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon
Hoth's current expectations and various assumptions. Hoth believes
there is a reasonable basis for its expectations and beliefs, but
they are inherently uncertain. Hoth may not realize its
expectations, and its beliefs may not prove correct. Actual results
could differ materially from those described or implied by such
forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption "Risk Factors" in Hoth's Form
10K for the period ending December 31, 2018, and Hoth's other
filings made with the Securities and Exchange Commission.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by law.
Contact
Investor Relations Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-to-present-to-investors-at-the-union-league-of-philadelphia-300866918.html
SOURCE Hoth Therapeutics, Inc.